Shopping Cart
- Remove All
- Your shopping cart is currently empty
Rg3039 (PF-06687859) is a potent DcpS inhibitor. DcpS is a therapeutic target for spinal muscular atrophy. Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene which produces an essential protein known as SMN. RG3039 improves motor function in SMA mice. RG3039 also showed activity to improve survival, function and motor unit pathologies in two SMA mouse models.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $32 | In Stock | |
5 mg | $51 | In Stock | |
10 mg | $84 | In Stock | |
25 mg | $165 | In Stock | |
50 mg | $272 | In Stock | |
100 mg | $438 | In Stock | |
500 mg | $985 | In Stock |
Description | Rg3039 (PF-06687859) is a potent DcpS inhibitor. DcpS is a therapeutic target for spinal muscular atrophy. Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene which produces an essential protein known as SMN. RG3039 improves motor function in SMA mice. RG3039 also showed activity to improve survival, function and motor unit pathologies in two SMA mouse models. |
Targets&IC50 | DcpS:0.069 nM. |
Alias | PF-06687859 |
Molecular Weight | 432.35 |
Formula | C21H23Cl2N5O |
Cas No. | 1005504-62-0 |
Smiles | Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1 |
Relative Density. | 1.375 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O: < 0.1 mg/mL (insoluble) DMSO: 1 mg/ml, Sonication is recommended. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.